Related Experiment Video
Updated: May 21, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Diffuse large B-cell lymphoma: current strategies and future directions
Jennifer L Cultrera1, Samir M Dalia
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA. Jennifer.Cultrera@moffitt.org
Cancer Control : Journal of the Moffitt Cancer Center
|June 20, 2012
Summary
Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma. Research is exploring new treatments like targeted therapies and drug combinations to improve outcomes for DLBCL patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma, accounting for 25-35% of annual cases.
- The incidence of DLBCL has doubled, necessitating improved treatment strategies.
Purpose of the Study:
- To review current DLBCL treatment protocols.
- To discuss emerging research in molecular diagnostics and prognostic factors for DLBCL.
Main Methods:
- Literature review of current DLBCL treatment protocols.
- Analysis of ongoing clinical trials and research findings.
Main Results:
- Patient responses to current therapies vary.
- The rituximab era has improved outcomes but novel approaches are needed for challenging cases.
- Promising results are emerging from trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates.
Conclusions:
- Advances in DLBCL care signal a shift towards personalized medicine.
- Ongoing studies focus on novel drug combinations and molecular targets for tailored DLBCL treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...